Results

Total Results: 1,544 records

Showing results for "drug".

421. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
     January 01, 2015 - the Methods section of the Executive Summary that we searched ClinicalTrials.gov and the Food and Drug … drug 1". … We have changed the legend for the hypoglycemia figure to say, "Fewer events with drug 2/drug 1." … What are the specific pros and cons of the choice of a second drug to add to metformin when greater … Note glibenclamide and glyburide are the same drug, right? Needs a table footnote.

422. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cad-women-treatment_research-protocol.pdf
     September 29, 2011 - to this posting, the following changes were included in the key questions: Adding ―adverse drug … What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug … What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug … What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug … The safety outcomes will be framed to help identify adverse events, including adverse drug reactions

423. Despite steadily increasing health care expenditures in the United States, improved health outcomes and quality remain elusive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medical-interventions-comparing_methods.pdf
     November 01, 2008 - led to a series of Medicare reforms passed by Congress in 2003. 3 These reforms included a new drug … Accessed November 2007. 3 Medicare Prescription Drug, Improvement, and Modernization Act of 2008

424. Despite steadily increasing health care expenditures in the United States, improved health outcomes and quality remain elusive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_slutsky_comparing_medical_interventions.pdf
     November 01, 2008 - led to a series of Medicare reforms passed by Congress in 2003. 3 These reforms included a new drug … Accessed November 2007. 3 Medicare Prescription Drug, Improvement, and Modernization Act of 2008

425. Topic Disposition: Evaluation and Management of Headaches in Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/headaches-pregnancy-topic-brief.pdf
     January 01, 2019 - Drug therapy for treating post-dural puncture headache. … Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. … Drug Saf. 2011 Aug 1;34(8):691-703. doi: 10.2165/11590370-000000000-00000. PMID: 21751829. 32. … Pharmacoepidemiol Drug Saf. 2016 May;25(5):493-502. doi: 10.1002/pds.3902. PMID: 26554750. … Drug therapy for treating post-dural puncture headache.

426. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_executive.pdf
     March 01, 2011 - Food and Drug Administration (FDA). … Two-drug combination therapies with metformin (such as metformin plus thiazolidinediones, metformin plus … Few studies included insulin added to oral medications or compared other two-drug combination therapies … We were unable to draw any useful conclusions about CHF risk from other drug comparisons of interest, … their results by the combination therapy, which includes the background medication(s) plus the study drug

427. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1306.pdf
     June 01, 2013 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … Food and Drug Administration (FDA) has approved intranasal oxytocin for inducing uterine contractions

428. Topic 0494 Tacrolimus Monitoring and Treatment Renal Transplantation NSD FINAL (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0583-131115.pdf
     March 13, 2013 - Cyclosporine, has a narrow therapeutic window between efficacy and toxicity, thereby requiring monitoring of drug … mainly as CNI-minimization, CNI-avoidance, or CNI-withdrawal protocols, seek to reduce the amount of drug

429. Crosscutting-Horizon-Scan-High-Impact-1312 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Digital Medicines (Proteus Digital Health Feedback System) for Chronic Conditions Requiring Long-term Drug … Food and Drug Administration for the monitoring device in March 2010 and marketing clearance for the … Once activated, the sensor transmits digital information regarding the drug taken, its dose, and time … Food and Drug Administration (FDA). 510(k) summary for Raisin personal monitor [K093976]. … Food and Drug Administration (FDA); 2010 Mar 25 [accessed 2010 Dec 27]. [10 p].

430. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/01_-arthritis_potential_high_impact_june_2012.pdf
     January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … lists the seven topics for which (1) preliminary phase III or later phase data were available for drug …  Key Expert Comments: Overall, experts thought that the drug might address the unmet need for a … Food and Drug Administration (FDA)-compliant manner will be needed in many locations where there may … tyrosine kinase inhibitor that is being investigated as a targeted disease-modifying antirheumatic drug

431. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-atrial-fibrillation_research-protocol.pdf
     January 30, 2012 - Food and Drug Administration (FDA)-approved low-molecular-weight heparins (e.g., bemiparin, certoparin … Food and Drug Administration; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding … We will use several approaches to identify relevant gray literature, including requests to drug and … Food and Drug Administration (FDA) device registration studies and new drug applications. … Food and Drug Administration GWTG Get With The Guidelines HAS-BLED hypertension, abnormal renal/liver

432. Microsoft Word - 3-DKE274__ACEI-ARB-DRI__Comments_Disposition_Table-21_Jan_2011 cyk _2_.docx (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update_disposition-comments.pdf
     October 07, 2011 - recommendation for the use of these products in any manner other than as approved by the Food and Drug … ONTARGET is that combination therapy had higher adverse event rates but no more benefit than a single drug … The key questions 1 and 2 specifically examine cardiovascular events and adverse events between drug … Consideration of drug specific characteristics such as variations in tissue specificity, side effect … Furthermore, we note that the report introduces some of the pharmacological differences between drug

433. - (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/crohns-disease-future_research.pdf
     July 01, 2016 - first biologic tumor necrosis factor (TNF)-alpha inhibitor, infliximab, was approved by the Food and Drug … New Drug Application & Biologic License Application Efficacy Supplements (Approved CY 2008) [Internet … New Drug Application & Biologic License Application Efficacy Supplements (Approved CY 2008) [Internet … : Cimzia Drug: Mesalamine Estimated enrollment: 24 Sponsor OR PI and Collaborator(s): Milton S. … : Adalimumab Drug: 6 Mercaptopurine Estimated enrollment: Sponsor OR PI and Collaborator(s):

434. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacological Interventions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-236-maternal-fetal-child-outcomes-disposition-comments.pdf
     April 15, 2021 - • The draft report included references to Food and Drug Administration letter categories for fetal … lot of studies did not specify the disorder (they were based on current vs. past exposure to the drug … treatment comparison data and the other comparator data in one table so that readers can sort by drug … The title of this table should be changed to “Drug labeling related to pregnancy and nursing”. … Calibration curves were constructed for each antipsychotic drug assay with free human plasma by the

435. Systematic Review of Intermittent Inhaled Corticosteroids and of Long-acting Muscarinic Antagonists for Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/asthma-pharmacologic-treatment_research-protocol.pdf
     December 27, 2016 - of the pharmacologic interventions include more than one class of medications, in which case one drug … some of the pharmacologic comparators include more than one class of medications, in which case one drug … the abstract stage consistent with the process described by the Methods Guide.10 FDA=Food and Drug … Published online September 14, 2016; republished December 27, 2016 10 not on the individual drug … Drug therapies either as individual or combination products of inhaled corticosteroids, long-acting

436. Restless-Legs Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_executive.pdf
     November 01, 2012 - Dopamine agonists can result in a treatment complication called augmentation, which is a drug-induced … Central, the International Controlled Trials Registry Platform (ICTRP), Clinicaltrials.gov, Food and Drug … Results We organized results by Key Question and by class of drug/therapy. … Four studies investigated multiple fixed doses of the drug in separate study arms.25,34,37,39 IRLS … Augmentation, a drug-induced exacerbation of the disease, can occur with dopaminergic drugs.

437. Disposition of Comments Report for The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
     September 29, 2014 - We have previously submitted comments to FDA regarding “Impact of Approved Drug Labeling on Chronic … Our prescription drug abuse project works to develop and support policies that will help reduce the … The Pew Charitable Trusts recognizes prescription drug abuse as a public health crisis in the United … iii Food and Drug Administration (FDA), “Public Health Advisory: Methadone Use for Pain Control May … A history of being prescribed controlled substances and risk of drug overdose death.

438. Kidney-Disease-Medicine Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_surveillance.pdf
     October 01, 2012 - would produce prima facie evidence that a conclusion was out of date, such as the withdrawal of a drug … Is the portion of the CER that is probably or certainly out of date an issue of safety (a drug withdrawn … from the market, a black box warning) or the availability of a new drug within class (the latter being … original key questions, the conclusions of the original report, the results of the literature and drug … screening.tw. or exp drug evaluation,preclinical/ 3. 1 not 2 4.

439. high-cholesterol-medicines-update-protocol-130516 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/high-cholestorol-medicines-update_research-protocol.pdf
     December 31, 2013 - The LDL target for moderate-risk patients is less than 130 mg/dL, but the threshold for starting drug … For moderate-risk patients with a 10-year CHD risk of 10 to 20 percent, providers should consider drug … above 130 mg/dL; whereas for moderate-risk patients with a 10-year CHD risk less than 10 percent, drug … Food and Drug Administration; HDL = high-density lipoprotein; IR = immediate release; LDL = low-density … Food and Drug Administration; HMG-CoA = 3-hydroxy-3-methyl-glutaryl- coenzyme A reductase; N/A = not

440. Disposition of Comments for Pulmonary Arterial Hypertension: Screening, Management, and Treatment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypertension-pulmonary-arterial_disposition-comments.pdf
     April 25, 2013 - I liked the clear guidance on BNP testing and the drug therapy sections. … or continued therapy with that drug plus the addition of a second drug. … to some “background” that included another PAH drug. … (i.e. lumping de novo tratment data with add-on treatment data for a given drug). … If, for example, drug A added to placebo results in an improvement of X, and when added to drug B (instead